Drug Discovery

The pharmaceutical industry is currently witnessing a seismic transition that rivals the historical shift from basic alchemy to modern chemistry, as digital precision begins to replace the traditional reliance on serendipitous discovery. Closed-loop systems where AI predictions are immediately

Although 75 percent of the public believes weight-loss drugs are used for cosmetic reasons, 66 percent still find their use to be socially acceptable in modern society. This fundamental shift in perception coincides with the rise of glucagon-like peptide-1 receptor agonists, which have

Evidence suggests that neuroinflammation in CAR T-cell patients can persist as a localized metabolic crisis even after systemic inflammatory markers in the bloodstream have been successfully reduced. This finding highlights the complex nature of Chimeric Antigen Receptor (CAR) T-cell therapy, a

A newly developed molecular shield consisting of a positively charged oligopeptide linked to two polyethylene glycol chains can transiently block the entry points of the liver. This innovation addresses a fundamental limitation in the field of genetic medicine, where the immense potential of

The transformation of discarded medical waste into a sophisticated fleet of microscopic couriers capable of delivering life-saving gene therapies directly to tumors represents a fundamental shift in how medicine interacts with the human body. In the current landscape of 2026, the primary challenge

The shift toward human-first data collection aims to prevent the loss of hundreds of millions of dollars caused by unforeseen safety issues in clinical trials. For decades, the pharmaceutical industry relied almost exclusively on animal models, yet nearly ninety percent of drugs that pass animal